Literature DB >> 14636364

Antidepressant-induced mania: an overview of current controversies.

Joseph F Goldberg1, Christine J Truman.   

Abstract

OBJECTIVE: The prevalence, characteristics, and possible risk factors associated with antidepressant-induced mania remain poorly described. The present review sought to identify published rates of antidepressant-induced mania and describe risk factors for its emergence.
METHODS: A MedLine search was conducted of journals that focused on mania or hypomania associated with recent antidepressant use. Data from published reports were augmented with relevant findings from recent clinical trials presented at scientific conferences.
RESULTS: Antidepressant-induced manias have been reported with all major antidepressant classes in a subgroup of about 20-40% of bipolar patients. Lithium may confer better protection against this outcome when compared with other standard mood stabilizers, although switch rates have been reported with comparable frequencies on or off mood stabilizers. Evidence across studies most consistently supports an elevated risk in patients with (i) previous antidepressant-induced manias, (ii) a bipolar family history, and (iii) exposure to multiple antidepressant trials.
CONCLUSION: About one-quarter to one-third of bipolar patients may be inherently susceptible to antidepressant-induced manias. Bipolar patients with a strong genetic loading for bipolar illness whose initial illness begins in adolescence or young adulthood may be especially at risk. Further efforts are needed to better identify high-vulnerability subgroups and differentiate illness-specific from medication-specific factors in mood destabilization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636364     DOI: 10.1046/j.1399-5618.2003.00067.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  46 in total

1.  Pharmacogenetics in mood disorder.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Curr Opin Psychiatry       Date:  2005-01       Impact factor: 4.741

2.  Bipolar spectrum disorders in primary care: optimising diagnosis and treatment.

Authors:  Daniel J Smith; Ajay Thapar; Sharon Simpson
Journal:  Br J Gen Pract       Date:  2010-05       Impact factor: 5.386

Review 3.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

4.  Bipolarity is important during treatment with antidepressants.

Authors:  Daniel J Smith; James T Walters
Journal:  BMJ       Date:  2007-02-17

Review 5.  Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms.

Authors:  Jun Chen; Yiru Fang; David E Kemp; Joseph R Calabrese; Keming Gao
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

6.  Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

7.  Mapping mania symptoms based on focal brain damage.

Authors:  Gonçalo Cotovio; Daniel Talmasov; J Bernardo Barahona-Corrêa; Joey Hsu; Suhan Senova; Ricardo Ribeiro; Louis Soussand; Ana Velosa; Vera Cruz E Silva; Natalia Rost; Ona Wu; Alexander L Cohen; Albino J Oliveira-Maia; Michael D Fox
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

8.  Neuropsychiatric manifestation after a stroke: newly developed symptoms or side-effect of drug?

Authors:  Eng Chai Tan; Noor Azah Aziz; Saharuddin Ahmad
Journal:  BMJ Case Rep       Date:  2012-08-18

Review 9.  Bipolar depression in pediatric populations : epidemiology and management.

Authors:  Victoria E Cosgrove; Donna Roybal; Kiki D Chang
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.